|Articles|November 1, 1999

The Clinical and Economic Impact of Pneumococcal Disease in the Pediatric Population
Volume 5
Issue 17 Suppl

Selected Abstracts

Download PDF: Selected Abstracts

Articles in this issue

over 26 years ago

Article

Participating Faculty

over 26 years ago

Article

Introduction

over 26 years ago

Article

Epidemiology of Pneumococcal Disease

over 26 years ago

Article

The Costs of Antimicrobial Treatment Failure in Acute Otitis Media

over 26 years ago

Article

Prevention of Pneumococcal Disease in High-Risk Pediatric Groups

over 26 years ago

Article

The Clinical Impact of Pneumococcal Conjugate Vaccines

over 26 years ago

Article

Economic Impact of Pneumococcal Conjugate Vaccine in Managed Care

over 26 years ago

Article

Into the Era of the Pneumococcal Conjugate Vaccine

over 26 years ago

Article

CME Quiz

over 26 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Selected Abstracts

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Selected Abstracts

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS